Nexalin Technology Inc. is an innovative leader in the medical technology sector, focused on revolutionizing the treatment landscape for neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. The company’s non-invasive therapies address critical mental health challenges, including anxiety, depression, and substance addiction, underscoring its dedication to enhancing patient outcomes and advancing mental health solutions. With a solid foundation in research and a strategic emphasis on leveraging burgeoning demand for advanced healthcare innovations, Nexalin is poised for significant growth in the evolving digital health marketplace, making it an attractive prospect for institutional investors.
| Revenue (TTM) | 275,580 |
| Gross Profit (TTM) | 225,950 |
| EBITDA | $-8.47M |
| Operating Margin | -14180.00% |
| Return on Equity | -319.70% |
| Return on Assets | -161.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.14 |
| Price-to-Book | 2.69 |
| Price-to-Sales (TTM) | 32.45 |
| EV/Revenue | 18.39 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -63.60% |
| Shares Outstanding | $21.54M |
| Float | $17.98M |
| % Insiders | 11.23% |
| % Institutions | 5.23% |
Volatility is currently contracting
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life
Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announced the successful completion of a series of high-level meetings in the United States and China focused on advancing the Company's global clinical strategy for the treatment of Alzheimer's disease and dementia related cognitive decline. These meetings, including a productive Q-Submission interaction with the U.S. Food and Drug Administration (FDA), represent key milestones in the preparation of Nexalin's De Novo application with the FDA for the treatment of Alzheimer's disease.
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
